Substib

orm PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 06275-034001

Filing Date

Application No. 08/601,005

Information Disclosure Statement by Applicant

(Use several sheets if necessary)

Applicant Kjell Bäckström et al.

DEC 27 2002

Group Art Unit

(37 CFR §1.98(b))

March 1, 1996 **U.S. Patent Documents** Filing Date Examiner Desig. Patent Class Subclass If Appropriate Patentee Number Issue Date Initial D Fowler 07/1961 2,992,645 AA 3,671,625 06/1972 Altounyan AB 07/1984 Azria AC 4,462,983 Wetterlin 06/1985 AD 4,524,769 Wetterlin ΑE 4,534,345 06/1985 08/1985 Alexander AF 4,537,772 Virtanen 4,668,218 05/1987 AG 03/1988 Alexander 4,731,360 AH Wetterlin et al. 03/1990 4,907,583 ΑI 05/1990 Zoltan et al. AJ 4,926,852 ΑK 5,122,127 06/1992 Stanley 03/1993 Velasquez et al. ΑL 5,192,548 10/1993 Ganderton et al. AM 5,254,330 Boardman et al. 5,260,306 11/1993 AN 02/1994 Stanley et al. 5,288,498 ΑO 06/1994 AP 5,320,094 Laube et al. 08/1994 Clark et al. AQ 5,341,800 Newhouse et al. 09/1994 AR 5,349,947 10/1994 Feldstein et al. 5,352,461 AS 12/1994 Johnson AT 5,376,359 12/1994 Ganderton et al. AU 5,376,386 01/1995 Boyes et al. ΑV 5,384,133 05/1995 Rubsamen AW 5,419,315 Hodson et al. 08/1995 5,437,271 ΑX 5,451,569 09/1995 Wong et al. AY 10/1995 Patton et al. ΑZ 5,458,135

Examiner Signature	Date Considered 10/70/2004
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	of in conformance and not considered. Include copy of this form with

Fassberg et al.

12/1995

AAA

5,474,759

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified

AMM

ANN

A00

6,051,256

6,306,440

04/2000

10/2001

(37 CFR §1.98(b))

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 06275-034001

Application No. 08/601,005

Information Disclosure Statement by Applicant (Use several sheets if necessary)

Applicant Kjell Bäckström et al.

Filing Date March 1, 1996

Group Art Unit 1619 (616

U.S. Patent Documents Filing Date Examiner Desig. Patent Issue Date Patentee Class Subclass If Appropriate ID Number Initial ABB 5,482,032 01/1996 Smith et al. 5,482,706 01/1996 Igari et al. ACC 02/2001 Bäckström et al. ADD 5,506,203 C1 5,518,998 C1 02/2001 Bäckström et al AEE AFF 08/1997 Bäckström et al 5,658,878 AGG 5,707,644 01/1998 Illum 05/1998 Bäckström et al AHH 5,747,445 Bäckström et al 11/1998 AII 5,830,853 01/1999 Weiner et al. AJJ 5,858,968 AKK 5,952,008 09/1999 Bäckström et al ALL 5,997,848 12/1999 Patton et al.

Platz et al.

Bäckström et al

	Foreig	n Patent Do	cuments or F	ublished Foreign P	atent A	pplication	าร	
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID D	Number	Date	Patent Office	Class	Subclass	Yes	No
汉	APP	43 556/93	01/1994	Australia				
	AQQ	EP 0 023 359 A2	07/1980	European Patent Office				
	ARR	0 122 036	10/1984	European Patent Office				
7	ASS	0 128 831	12/1984	European Patent Office				
	ATT	0 312 052 A1	10/1987	European Patent Office				
	AUU	0 364 235 A1	04/1988	European Patent Office				
	AVV	0 272 097	06/1988	European Patent Office				
	AWW	0 360 340 A1	03/1990	European Patent Office				
	AXX	0 455 463	11/1991	European Patent Office				
X	AYY	0 383 751	09/1994	European Patent Office				

Examiner Signature Alba	Date Considered (0/30/2004
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	
	Substitute Disclosure Form (PTO-1449)

Substitute from PTO-1449 (Modifiant

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 06275-034001

Application No. 08/601,005

Information Disclosure Statement by Applicant (Use several sheets if necessary) Applicant Kjell Bäckström et al.

Filing Date March 1, 1996 Group Art Unit 1619 (66

(37 CFR §1.98(b))

Foreign Patent Documents or Published Foreign Patent Applications Translation Publication Country or Document Examiner Desig. Patent Office Date Class Subclass Number ID Initial 01/1988 AZZ JP 632 932 Japan JP 1 117 825 05/1989 Japan AAAA 02/1992 ABBB JP 4 041 421 Japan JP 4 149 126 05/1992 ACCC Japan DEG 27 2002 11/1986 Sweden **ADDD** 8 807 820 TECH CENTER 1600/2900 08/1971 United Kingdom AEEE 1 242 211 **AFFF** 1 520 247 08/1978 United Kingdom 06/1980 1 569 611 United Kingdom **AGGG** WO 87/05213 09/1987 WIPO AHHH Αl AIII WO 90/04962 05/1990 WIPO WO 91/16882 11/1991 WIPO AJJJ WIPO AKKK WO 91/16929 11/1991 WO 91/18091 11/1991 WIPO ALLL A1 WIPO WO 92/04069 03/1992 **AMMM** 04/1992 **WIPO** ANNN WO 92/06704 WIPO WO 93/25198 12/1993 A000 10/1994 APPP WO 94/22461 WIPO **WIPO** 01/1995 **AQQQ** WO 95/00151 WIPO WO 95/00128 01/1995 ARRR WIPO -ASSS WO 96/19206 06/1996 WO 96/19207 06/1996 WIPO ATTT AUUU

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner	Desig.	
Initial	מו	Document
丈	AVVV	Almer et al. "Insulin Inhalation - At Last A Breakthrough," Diabetes Res. And Clin. Pract., 5:s163 (1988).

Examiner Signature	Date Considered 10/30/2004
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	
	Substitute Disclosure Form (PTO-1449)

Sheet 4 of 6

Substitute Form PTO-1499

(Mooried)

U.S. Department of Patent and Trade

Information Disclosure Statement

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 06275-034001

Applicant

by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))

Kjell Bäckström et al. Filing Date March 1, 1996

	~	1 *V*/IAI'A *VIII .EAI'
Exam	Othe	er Documents (include Author Title Date of 1819) 1619 (6/16/16/16/16/16/16/16/16/16/16/16/16/16
Initi	al De	er Documents (include Author, Title, Date, and Place of Publication)
L		
\exists	AW	Aungst and Rogers, "Comparison of the Effects of Various Transmucosal Absorption Promoters Buccal Insulin Delivery," Int. J. Pharm. (Netherlands), 53/3, 227-235 (1980)
9		Buccal Insulin Delivery," Int. J. Pharm. (Netherlands), 53/3, 227-235 (1989).
$-\bot$	AX	(1990) 187 102 (1990).
- 1	AY	Björk et al., "Characterization of degradable starch" International Journal of Pharmaceutics, Brange et al. "Monomories I. " Brange et al. "Monomories II."
	AI	Brange et al., "Monomeric Insulins and Their Experimental and Clinical Implications," Diabetes Care, 13:923-954 (1990).
- 1	AZZ	Byron et al., "Drug Delivery via the Respiratory," Journal of Aerosol Medicine, 7:49-75 (1994) Chien et al., "Intranasal Drug Delivery for Systemic Medications." CROS Automatic Proceedings of the Company of the C
		Chien et al., "Journal of Aerosol Medicine 7, 40 as a
	AAA	Chien et al., "Intranasal Drug Delivery for Systemic Medications," CRC Critical Reviews in Chien et al., "Potential Systems, 4:67-194 (1987).
	ABBI	Therapeutic Drug Carrier Systems, 4:67-194 (1987). Chien et al., "Potential Developments in Systemic Delivery of Insulin," Drug Development and Colthorne et al. "The Physical Reviews in Systemic Delivery of Insulin," Drug Development and Colthorne et al. "The Physical Reviews in Systemic Delivery of Insulin," Drug Development and Colthorne et al. "The Physical Reviews in Systemic Delivery of Insulin," Drug Development and Colthorne et al. "The Physical Reviews in Systemic Medications," CRC Critical Reviews in Insulin, "Drug Development and Colthorne et al." The Physical Reviews in Systemic Medications, "CRC Critical Reviews in Insulin," Drug Development and Insulin, "Drug Development and Insulin, "Drug Development and Insulin," Drug Development and Insulin, "Drug
	ADDI	Industrial Pharman, 15(1)
ı	ACCC	Colthorpe et al., "The Pharmacelinistic Coltho
		Intratracheal " Di
- 1	ADDD	Dahlbäck et al., "Deposition of Tracer Association of No. 6, pp. 764-769 (1992).
		DURNIE VAL IV XI. C WI UN NADDI Recognization. To
- 1	AEEE	Daniback et al., "Regional Administration of Drugs to the Dall is
7		Dahlbäck et al., "Regional Administration of Drugs to the Rabbit Respiratory Tract," Journal of Aeros Absorption," Journal of Aerosol Medicine, 1:222-223 (1988).
	AFFFI	709. (1993) Anabolic Actions of Parathyroid Hormone on Bone. Ford
	AGGG	Dempster et al., Anabolic Actions of Parathyroid Hormone on Bone, Endocrine Reviews 14: 690-
	+	
1	АННН	The Diabetes Control and Complications Trial Research Group 1973.
		of Diacoles on the Development of the Diacoles of the Control of t
	AIIII	
	 	Emott et al., Parenteral absorption of:
	AJJJ	Eppstein and Longenecker, "Alternative Delivery Systems 6- P
	AKKKK	Eppstein and Longenecker, "Alternative Delivery Systems for Peptides and Proteins As Drugs," CRC Critical Reviews in Therapeutic Drug Carrier Systems, 5:99-139 (1988).
+	MAN	Goill et al., "Palmitoylcarnitine a surface.
	ALLLL	Goni et al., "Palmitoylcarnitine, a surface-active metabolite," FEBS Lett., Vol. 390, pp. 1-5 (1996). Hoover et al., "Peptides are Better Absorbed from the Lung than the Gut in the Rat," Jacobs Manual Research, Vol. 9, No. 8, pp. 1103-1106 (1903).
 	 	
	AMMMM	Jacobs, Maarten A I M. wrs. pt
	43000	Jacobs, Maarten A.J.M., "The Pharmacodynamics and Activity of Intranasally Administered Insulin In Healthy Male Volunteers," <i>Diabetes</i> , Vol. 42, pp. 1649-1655 (1993).
4	ANNNN	Jaegfeldt, H. et al., "Particle size distribution from different modifications of Turbuhaler®," Jones, "Pulmonary et al.," Indianasally Administered Insulin different modifications of Turbuhaler®," Jones, "Pulmonary et al.," Indianasally Administered Insulin different modifications of Turbuhaler®,"
1 1	A0000	Proceedings of an international workshop on a new inhaler, May 21-22, 1987 (London) pp. 90-99. University of Wales United Vices.
+	70000	Jones, "Pulmonary absorption of insulin", (1998) Ph.D. Thesis, Welsh School of Pharmacy,
1 1	APPPP	Köhler, Dieter "Aerosol- C. C.
	40000	Köhler, Dieter, "Aerosols for Systemic Treatment," Lung, Supplement: 677-684 (1990).
1		isulin. Aton-w Lungaria Literatura de la lancaria de la lingaria de la lingaria de la lingaria de la lancaria d
7	ARRRR I	Köhler et al., "Nicht radioaktives Verfahren zur Messung der Lungenpermeabilitat: Inhalation von insulin," Aten-w-Lungenkrkh, Jahrgang 13, Nr. Jun. 1987; 230-232. 29:1035-1036 (1993).
. ——	· ~~~~~ 3	29:1035-1036 (1993)
		1030 (1993).

	Evenia		,,
	Examiner Signature		
ı			
1	\sim	Date Considered	
ļ			
1	EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	1 10130/2001	
I	The state of the s	1	→
Ĺ	next communication to applicable. Draw line through citation if no	ot in and	1
	anti-	of in conformance and not considered to the	<u></u>
		THE THE CONSIDERED. INClude CODY O	f this form with
			I THE TOTAL MICH
		Substitute Di	

OLF 1 1002 W

Form PTO-1449

next communication to applicant.

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 06275-034001

March 1, 1996

Applicant

Application No. 08/601,005

Information Disclosure Statement by Applicant

(Use several sheets if necessary)

Kjell Bäckström et al.

Group Art Unit 8

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication) Examiner Desig. Document ID Initial Laube et al., "Preliminary Study of the Efficacy of Insulin Aerosol Delivery by Oral Inhalation in ASSSS Diabetic Patients," Journal of the American Medical Association, 239:2106-2109 (1993). Lecluyse et al., "In Vitro Effects of Long-Chain Acylcarnitines on the Permeability, Transepithelial Electrical Resistance and Morphology of Rat Colonic Mucosa," J. Pharmacol. Exp. Ther., Vol. ATTTT 265(2), pp. 955-62 (1993). Lee et al., "Development of an aerosol dosage form containing insulin," Journal of Pharmaceutical AUUUU Sciences, Vol. 65, No. 4, pp. 567-574 (1976). Li, Yuping et al., "Effect of a Conjugated Bile Salt on the Pulmonary Absorption of Insulin in Rats," AVVVV Eur. J. Pharm. Biopharm., Vol. 39, pp. 216-221 (1993). Liu et al., "Pulmonary Delivery of Free...," Pharmaceutical Research, 10:228-232 (1993). ₩WWWA Longenecker et al., "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in **AXXXX** Sheep," J. Pharm. Sci., 76(5): 351-355 (1987). Mizgala et al., "Renal Handling of Phosphate," Physiological Reviews, 65(2): 431-466 (1985). AYYYY Nagai et al., "Powder Dosage Form of Insulin for Nasal Administration," J. Controlled Release. **AZZZZ** 1:15-22 (1984). Nagano et al., "New Method of Insulin...," Jikeikai Medical Journal, 32: 503-506 (1985). AAAAAANewman, "Chapter 9: Therapeutic aerosols", In: Aerosols and the Lung: Clinical and Experimental ABBBBB Aspects, (1984) Butterworth & Co., United Kingdom. O'Hagan and Illum, "Absorption of Peptides and Proteins from the Respiratory Tract and the Potential for Development of Locally Administered Vaccine," Critical Reviews in Therapeutic Drug ACCCCC Carrier Sys, 7:35-97 (1990). Okumura et al., "Intratracheal delivery of insulin absorption from solution and aerosol by rat lung." ADDDDD International Journal of Pharmaceutics, Vol. 88, pp. 63-73 (1992). Olanoff et al., "Method to Enhance Intranasal Peptide Delivery," in "Controlled-Release Technology AEEEEE Pharmaceutical Applications", Lee et al, American Chemical Society, 301-309 (1987). Patton et al., "Bioavailability of Pulmonary Delivered Peptides and Proteins: α-interferon, **AFFFFF** Calcitonins and Parathyroid Hormones," Journal of Controlled Release, 28: 79-85 (1994). Patton et al., "(D) Routes of Delivery: Case Studies," Advanced Drug Delivery Reviews, Vol 8, pp. AGGGG(179-196 (1992). Reeve et al., Anabolic Effect of Human Parathyroid Hormone Fragment on Trabecular Bone in АНННН Involutional Osteoporosis: A Multicentre Trial, British Medical Journal, pp. 1340-1344, (1980). Remington's Pharmaceutical Science, 18th edition., p. 1079 (1990). AIIIII Ruin, "Diabetics May Not Need Their Insulin Shots," article in Sydsvenska (Dagbladet), Monday, AJJJJJ Jun. 12, 1989. Sakr., "A new approach for insulin...," International Journal of Pharmaceutics, 86:1-7 (1992). AKKKKK Salzman et al., "Intranasal Aerosolized Insulin Mixed-Meal Studies and Long-term Use in Type 1 ALLLLI Diabetes," The New England Journal of Medicine, I312:1078-1084 (1985). Schanker et al., "Species Comparison of Drug Absorption from the Lung Aerosol Inhalation or MMMM Intratracheal Injection," Drug Metabolism & Disposition, Vol. 14, pp. 79-88 (1986).

A_{-}	
Examiner Signature	Date Considered
EYAMINER: Initials citation considered. Draw line through citation	ion if not in conformance and not considered. Include copy of this form

Substitute Disclosure Form (PTO-1449)

Substitute Form

Substitute Form PTO-1449

(37 CFR §1.98(b))

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 06275-034001

Application No. 08/601,005

Information Disclosure Statement by Applicant

(Use several sheets if necessary)

Applicant Kjell Bäckström et al.

Filing Date

March 1, 1996

Group Art Unit

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig.	Document
70	ANNNN	Schluter et al., "Pulmonary Administration Type 1 Diabetics" Abstract #298, Diabetes, 33 (Supplement): 75A (1984).
	A00000	Selam and Charles, "Devices for Insulin Administration," Diabetes Care, 13:955-979 (1990).
	APPPPP	Timsina et al., "Drug Delivery to the Respiratory Tract Using Dry Powder Inhalers," Int. J. Pharmaceutics, 101:1-13 (1994).
	AQQQQQ	Wang et al., Parenteral Science and Technology, 42 (2S), S4-S26, 1988.
	ARRRRR	Pharmaceutical Research, vol. 3, pp. 300-308, (1986).
	ASSSSS	Wigley et al., "Insulin Across Respiratory Mucosae by Aerosol Delivery," Diabetes, 20:552-556 (1971).
	ATITTT	Yamamoto et al., "Absorption Enhancement of Intrapulmonary Administered Insulin by Various Absorption," J. Pharm. Pharmacol., Vol. 46, pp. 14-18 (1994).
	AUUUUL	Zingg et al., "Transhepatic Absorption and Biliary Excretion of Insulin," Can. J. Physiol. Pharmacol., 65:1982-1987 (1987).

DEC 17 mg

TECH CENTER : JO/2900

RECEIVED

DEC 27 2002

TECH CENTER 1600/2900

.1	
Examiner Signature 7	Date Considered /
1/2	10/29/7004
M Con	1411301 CW 4
70	
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	
110.1. 00.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	Substitute Disclosure Form (PTO-1449)